Human pluripotent stem cells in drug discovery and predictive toxicology

被引:65
|
作者
Laustriat, Delphine [1 ]
Gide, Jacqueline [2 ]
Peschanski, Marc [1 ]
机构
[1] I STEM, AFM, INSERM, UEVE U861, F-91030 Evry, France
[2] I STEM, AFM, CECS, F-91030 Evry, France
关键词
human embryonic stem cell; induced pluripotent stem cell; pathological modelling; pharmacology; toxicology; INDUCED DEVELOPMENTAL TOXICITY; VITRO EMBRYOTOXICITY TESTS; EFFICIENT DIFFERENTIATION; GENETIC-DISORDERS; DEFINED FACTORS; IN-VIVO; LINES; HEPATOCYTES; VALIDATION; GENERATION;
D O I
10.1042/BST0381051
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human pluripotent stem cells are a biological resource most commonly considered for their potential in cell therapy or, as it is now called, 'regenerative medicine'. However, in the near future, their most important application for human health may well be totally different, as they are more and more envisioned as opening new routes for pharmacological research. Pluripotent stem cells indeed possess the main attributes that make them theoretically fully equipped for the development of cell-based assays in the fields of drug discovery and predictive toxicology. These cells are characterized by: (i) an unlimited self-renewal capacity, which make them an inexhaustible source of cells; (ii) the potential to differentiate into any cell phenotype of the body at any stage of differentiation, with probably the notable exception, however, of the most mature forms of many lineages; and (iii) the ability to express genotypes of interest via the selection of donors, whether they be of embryonic origin, through pre-implantation genetic diagnosis, or adults, by genetic reprogramming of somatic cells, so-called iPSCs (induced pluripotent stem cells). In the present review, we provide diverse illustrations of the use of pluripotent stem cells in drug discovery and predictive toxicology, using either human embryonic stem cell lines or iPSC lines.
引用
收藏
页码:1051 / 1057
页数:7
相关论文
共 50 条
  • [21] Integrating Human Pluripotent Stem Cells into Drug Development
    Engle, Sandra J.
    Puppala, Dinesh
    CELL STEM CELL, 2013, 12 (06) : 669 - 677
  • [22] Converging technologies to enable induced pluripotent stem cells in drug discovery
    Flynn, Peter
    Yingling, Jessica
    Shoemaker, Dan
    REGENERATIVE MEDICINE, 2010, 5 (04) : 489 - 491
  • [23] Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
    Beghini, Daniela Gois
    Kasai-Brunswick, Tais Hanae
    Henriques-Pons, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [24] Induced pluripotent stem cells — opportunities for disease modelling and drug discovery
    Marica Grskovic
    Ashkan Javaherian
    Berta Strulovici
    George Q. Daley
    Nature Reviews Drug Discovery, 2011, 10 : 915 - 929
  • [25] Induced pluripotent stem cells - opportunities for disease modelling and drug discovery
    Grskovic, Marica
    Javaherian, Ashkan
    Strulovici, Berta
    Daley, George Q.
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (12) : 915 - 929
  • [26] The use of stem cells in discovery and toxicology
    Ruffner, Heinz
    Jaffe, Aron
    Wiellette, Elizabeth
    Mueller, Matthias
    Parker, Christian
    Bouwmeester, Tewis
    TOXICOLOGY LETTERS, 2013, 221 : S9 - S9
  • [27] Perspectives of future lung toxicology studies using human pluripotent stem cells
    Masui, Atsushi
    Hirai, Toyohiro
    Gotoh, Shimpei
    ARCHIVES OF TOXICOLOGY, 2022, 96 (02) : 389 - 402
  • [28] Perspectives of future lung toxicology studies using human pluripotent stem cells
    Atsushi Masui
    Toyohiro Hirai
    Shimpei Gotoh
    Archives of Toxicology, 2022, 96 : 389 - 402
  • [29] Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery
    Jiho Jang
    Jeong-Eun Yoo
    Jeong-Ah Lee
    Dongjin R Lee
    Ji Young Kim
    Yong Jun Huh
    Dae-Sung Kim
    Chul-Yong Park
    Dong-Youn Hwang
    Han-Soo Kim
    Hoon-Chul Kang
    Dong-Wook Kim
    Experimental & Molecular Medicine, 2012, 44 : 202 - 213